<DOC>
	<DOCNO>NCT00364143</DOCNO>
	<brief_summary>The purpose study determine whether IHL-305 ( irinotecan liposome injection ) safe effective treatment advance solid tumor .</brief_summary>
	<brief_title>Safety Study IHL-305 ( Irinotecan Liposome Injection ) Treat Advanced Solid Tumors</brief_title>
	<detailed_description>This Phase I dose-escalation study intravenous administration IHL-305 patient advance solid tumor . Patients receive IHL-305 intravenous infusion 60 minute Day 1 follow 27-day observation period total 28 day ( 4 week ) per cycle . Two patient population evaluate separately ; patient UGT1A1*28 genotype homozygous wild-type ( wt/wt ) heterozygous ( wt/*28 ) variants one group , patient UGT1A1*28 homozygous variant ( *28/*28 ) another group .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Histologically confirm malignant solid tumor candidate know regimen protocol treatment higher efficacy priority 2 . Failed conventional therapy cancer malignancy conventional therapy exist 3 . Recovered acute adverse effect prior therapy , exclude alopecia ( hair loss ) 4 . ECOG performance status 0 , 1 , 2 5 . 18 year age old 6 . Normal organ bone marrow function define : absolute neutrophil count great equal 1,500 cells/microliter platelet great equal 100,000 cells/microliter total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) less equal 2.5 x institutional upper limit normal ( ULN ) less equal 5.0 x ULN patient liver metastasis plasma creatinine less equal 1.5 x institutional ULN OR creatinine clearance great equal 60 mL/min/1.73 m2 patient creatinine level institutional normal 7 . Ability understand willingness sign write informed consent document 1 . Previously treat irinotecan , chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study , recover adverse effect due agent administer 4 week earlier 2 . Receiving investigational agent 3 . Known brain metastasis 4 . History allergic reaction attribute compound similar chemical composition IHL305 5 . Concurrent serious infection ( i.e. , require intravenous antibiotic ) 6 . Pregnant woman woman childbearing potential use method avoid pregnancy ; negative pregnancy test ( urine serum ) must document baseline woman childbearing potential ; breastfeed study . 7 . Uncontrolled intercurrent illness include , limited , ongoing active infection , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement 8 . Significant cardiac disease include heart failure meet New York Heart Association ( NYHA ) class III IV definition ; history myocardial infarction within one year study entry ; uncontrolled dysrhythmias ; poorly control angina . 9 . History serious ventricular arrhythmia ( ventricular tachycardia [ VT ] ventricular fibrillation [ VF ] , great equal 3 beat row ) ; QTc great equal 450 msec men 470 msec woman ; leave ventricular ejection fraction ( LVEF ) less equal 40 % multigated acquisition scan ( MUGA ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Advanced Solid Tumor</keyword>
	<keyword>Oncology</keyword>
</DOC>